Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in Drugs

Retrieve available abstracts of 28 articles:
HTML format



Single Articles


    March 2022
  1. LAMB YN
    Nirmatrelvir Plus Ritonavir: First Approval.
    Drugs. 2022 Mar 19. pii: 10.1007/s40265-022-01692.
    PubMed     Abstract available


  2. HEO YA
    Sotrovimab: First Approval.
    Drugs. 2022;82:477-484.
    PubMed     Abstract available


  3. SYED YY
    Molnupiravir: First Approval.
    Drugs. 2022;82:455-460.
    PubMed     Abstract available


    February 2022
  4. MAZZA MG, Vai B, De Picker L, Benedetti F, et al
    Comment on: "Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:349-351.
    PubMed    


  5. LENZE EJ, Reiersen AM, Facente SN
    Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence".
    Drugs. 2022;82:353-354.
    PubMed    


    January 2022
  6. RIZK JG, Wenziger C, Tran D, Hashemi L, et al
    Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.
    Drugs. 2022;82:43-54.
    PubMed     Abstract available


    December 2021
  7. FACENTE SN, Reiersen AM, Lenze EJ, Boulware DR, et al
    Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Drugs. 2021;81:2081-2089.
    PubMed     Abstract available


  8. SYED YY
    Regdanvimab: First Approval.
    Drugs. 2021;81:2133-2137.
    PubMed     Abstract available


    November 2021
  9. DEEKS ED
    Casirivimab/Imdevimab: First Approval.
    Drugs. 2021;81:2047-2055.
    PubMed     Abstract available


    September 2021
  10. AHMED N, Pezacki JP
    Reply to Zhang and Zhu "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1693-1695.
    PubMed    


  11. ZHANG S, Zhu F
    Comment on: "MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19".
    Drugs. 2021;81:1691-1692.
    PubMed    


    July 2021
  12. ROE MT, Patrick-Lake B, von Eschenbach AC
    Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments.
    Drugs. 2021;81:1235-1237.
    PubMed    


    June 2021
  13. VUORIO A, Kovanen PT
    Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
    Drugs. 2021;81:1125-1127.
    PubMed    


    April 2021
  14. HEO YA
    Voclosporin: First Approval.
    Drugs. 2021;81:605-610.
    PubMed     Abstract available


  15. HUM C, Loiselle J, Ahmed N, Shaw TA, et al
    MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
    Drugs. 2021;81:517-531.
    PubMed     Abstract available


  16. TORRES-PENA JD, Perez-Belmonte LM, Fuentes-Jimenez F, Lopez Carmona MD, et al
    Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.
    Drugs. 2021;81:685-695.
    PubMed     Abstract available


    March 2021
  17. LAMB YN
    BNT162b2 mRNA COVID-19 Vaccine: First Approval.
    Drugs. 2021;81:495-501.
    PubMed     Abstract available


    December 2020
  18. LIN KJ, Schneeweiss S, Tesfaye H, D'Andrea E, et al
    Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity.
    Drugs. 2020;80:1961-1972.
    PubMed     Abstract available


    October 2020
  19. CANTINI F, Goletti D, Petrone L, Najafi Fard S, et al
    Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
    Drugs. 2020 Oct 17. pii: 10.1007/s40265-020-01421.
    PubMed     Abstract available


  20. HAJRA A, Mathai SV, Ball S, Bandyopadhyay D, et al
    Management of Thrombotic Complications in COVID-19: An Update.
    Drugs. 2020;80:1553-1562.
    PubMed     Abstract available


    September 2020
  21. LAMB YN
    Remdesivir: First Approval.
    Drugs. 2020;80:1355-1363.
    PubMed     Abstract available


  22. RIZK JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al
    Pharmaco-Immunomodulatory Therapy in COVID-19.
    Drugs. 2020;80:1267-1292.
    PubMed     Abstract available


  23. VRACHATIS DA, Giotaki SG, Giannopoulos G, Deftereos S, et al
    Comment on: "Pharmaco-Immunomodulatory Therapy in COVID-19".
    Drugs. 2020;80:1499-1500.
    PubMed    


  24. RIZK JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, et al
    Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19".
    Drugs. 2020;80:1501-1503.
    PubMed    


  25. BIANCONI V, Violi F, Fallarino F, Pignatelli P, et al
    Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
    Drugs. 2020;80:1383-1396.
    PubMed     Abstract available


    July 2020
  26. PANERA N, Tozzi AE, Alisi A
    The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.
    Drugs. 2020;80:941-946.
    PubMed     Abstract available


    June 2020
  27. SHIRLEY M
    Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.
    Drugs. 2020 Jun 29. pii: 10.1007/s40265-020-01350.
    PubMed     Abstract available


    November 2019
  28. LAMB YN
    Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax((R)) Tetra/Flucelvax Quadrivalent((R))): A Review in the Prevention of Influenza.
    Drugs. 2019 Nov 25. pii: 10.1007/s40265-019-01237.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: